For Q1 FY2026 ended March 31, 2026, NewAmsterdam Pharma reported revenue of $3.04 million, up 208.2% year-over-year. Net loss widened to $48.4 million from $39.5 million, while operating loss was $58.4 million. Diluted EPS was -$0.40, compared to -$0.34 a year ago. The company held $457.6 million in cash and $665.2 million in equity, with no long-term debt.
•Revenue increased 208.2% YoY to $3.04 million.
•Net loss expanded 22.6% to $48.4 million.
•Operating loss grew 15.2% to $58.4 million.
•Cash and equivalents stood at $457.6 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. It also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
What does NewAmsterdam Pharma Company N.V. (NAMS) do?
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. Its lead product candidate is Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib is being studied in clinical trials as a monotherapy and in combination with ezetimibe to lower LDL-C (bad cholesterol) for cardiovascular diseases. Additionally, the company is exploring Obicetrapib in a Phase 2a clinical trial for Alzheimer's disease. The company aims to enhance patient care in populations with cardiometabolic conditions by addressing unmet medical needs in lipid management and related disorders.
Where is NewAmsterdam Pharma (NAMS) listed and what currency is used?
NewAmsterdam Pharma Company N.V. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol NAMS. The stock is traded in U.S. dollars (USD), reflecting its listing on a U.S. exchange. The company's headquarters is in Naarden, the Netherlands, but its shares are accessible to international investors through the Nasdaq exchange. The choice of a U.S. listing provides liquidity and visibility among global investors, particularly those interested in the biotechnology and healthcare sectors.
What sector and industry does NewAmsterdam Pharma (NAMS) operate in?
NewAmsterdam Pharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on researching and developing innovative therapies for serious medical conditions. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. NewAmsterdam's work in cardiometabolic diseases places it at the intersection of cardiovascular health and metabolic disorders, targeting conditions like high cholesterol and potentially Alzheimer's disease through its CETP inhibitor platform.
Where is NewAmsterdam Pharma (NAMS) headquartered and what markets does it serve?
NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. The company operates in the United States region, as indicated by its listing on the Nasdaq and its focus on U.S. regulatory pathways. While its primary market is the United States, its therapies are intended for global populations with cardiometabolic diseases. The company's late-stage clinical trials and development efforts are likely conducted internationally, but its corporate base remains in the Netherlands. The combination of a Dutch headquarters and a U.S. exchange listing reflects a strategy to leverage European research capabilities while accessing American capital markets.
What is NewAmsterdam Pharma's (NAMS) main product candidate and how does it work?
NewAmsterdam Pharma's main product candidate is Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors work by blocking the transfer of cholesterol from HDL (good cholesterol) to LDL (bad cholesterol) and other lipoproteins, thereby raising HDL levels and lowering LDL-C. Obicetrapib is being developed as a monotherapy and in combination with ezetimibe, a common cholesterol-lowering drug, to reduce LDL-C for cardiovascular diseases. Additionally, the company is investigating Obicetrapib in a Phase 2a clinical trial for Alzheimer's disease, suggesting potential broader applications beyond cardiometabolic conditions. This dual focus on cardiovascular and neurological diseases highlights the company's innovative approach to addressing major health challenges.